If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX(1-800-545-5979)
bamlanivimab and etesevimab together
bamlanivimab and etesevimab together
700mg/1400mgHCP Fact Sheet | Patient & Caregiver Fact Sheet | FDA Authorization Letter
Bamlanivimab and etesevimab are authorized to be administered together in adults and pediatric patients, including neonates, who are at high risk for progression to severe coronavirus disease 2019 (COVID-19), including hospitalization or death for
For information on the authorized use of bamlanivimab and etesevimab together and mandatory requirements under the emergency use authorization (EUA), please review the FDA Letter of Authorization, Fact Sheet for Healthcare Providers, and Fact Sheet for Patients/Caregivers at www.LillyAntibody.com.
Contact Lilly
Call Us
If you have immediate questions regarding COVID-19, or to report an Adverse Event or Product Complaint, please call us.
Daily Live Support: 9am to 7pm ET.
After Hours: Call Back Support Available